Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07200908

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Sponsor: Mirum Pharmaceuticals, Inc.

Conditions Chronic Hepatitis D Infection

Interventions Brelovitug 300 mg Bulevirtide 2 mg and Brelovitug - 300 mg

Updated 5 times since 2025 Last updated: Feb 26, 2026 Started: Aug 27, 2025 Primary completion: Jun 30, 2027 Completion: Sep 30, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07200908, this PHASE3 trial focuses on Chronic Hepatitis D Infection and remains actively recruiting participants. Sponsored by Mirum Pharmaceuticals, Inc., it has been updated 5 times since 2025, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE3
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE3

First recorded

Aug 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mirum Pharmaceuticals, Inc.

Data source: Mirum Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almería, Spain , Barcelona, Spain , Birmingham, United Kingdom , Brno, Czechia , Bucharest, Romania , Clermont-Ferrand, France , Clichy, France , Cottingham, United Kingdom , Créteil, France , Düsseldorf, Germany and 26 more locations